These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 27666541)

  • 1. Enhanced anti-tumor immunity against breast cancer induced by whole tumor cell vaccines genetically modified expressing α-Gal epitopes.
    Xue D; Liang Y; Duan S; He J; Su J; Zhu J; Hu N; Liu J; Zhao Y; Lu X
    Oncol Rep; 2016 Nov; 36(5):2843-2851. PubMed ID: 27666541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase.
    LaTemple DC; Abrams JT; Zhang SY; Galili U
    Cancer Res; 1999 Jul; 59(14):3417-23. PubMed ID: 10416604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Melanoma differentiation-associated gene-7 (mda-7)/interleukin (IL)-24 induces anticancer immunity in a syngeneic murine model.
    Miyahara R; Banerjee S; Kawano K; Efferson C; Tsuda N; Miyahara Y; Ioannides CG; Chada S; Ramesh R
    Cancer Gene Ther; 2006 Aug; 13(8):753-61. PubMed ID: 16543916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunity to the alpha(1,3)galactosyl epitope provides protection in mice challenged with colon cancer cells expressing alpha(1,3)galactosyl-transferase: a novel suicide gene for cancer gene therapy.
    Unfer RC; Hellrung D; Link CJ
    Cancer Res; 2003 Mar; 63(5):987-93. PubMed ID: 12615713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epithelial ovarian cancer stem-like cells expressing α-gal epitopes increase the immunogenicity of tumor associated antigens.
    Yao X; Dong Z; Zhang Q; Wang Q; Lai D
    BMC Cancer; 2015 Dec; 15():956. PubMed ID: 26673159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pancreatic cancer immunotherapy using a tumor lysate vaccine, engineered to express α-gal epitopes, targets pancreatic cancer stem cells.
    Tanida T; Tanemura M; Miyoshi E; Nagano H; Furukawa K; Nonaka Y; Akita H; Hama N; Wada H; Kawamoto K; Kobayashi S; Eguchi H; Mori M; Doki Y
    Int J Oncol; 2015 Jan; 46(1):78-90. PubMed ID: 25354268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization.
    Rekoske BT; Smith HA; Olson BM; Maricque BB; McNeel DG
    Cancer Immunol Res; 2015 Aug; 3(8):946-55. PubMed ID: 26041735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A practical approach to pancreatic cancer immunotherapy using resected tumor lysate vaccines processed to express α-gal epitopes.
    Furukawa K; Tanemura M; Miyoshi E; Eguchi H; Nagano H; Matsunami K; Nagaoka S; Yamada D; Asaoka T; Noda T; Wada H; Kawamoto K; Goto K; Taniyama K; Mori M; Doki Y
    PLoS One; 2017; 12(10):e0184901. PubMed ID: 29077749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic melanoma vaccine expressing alphaGal epitopes induces antitumor immunity to autologous antigens in mice without signs of toxicity.
    Rossi GR; Mautino MR; Awwad DZ; Husske K; Lejukole H; Koenigsfeld M; Ramsey WJ; Vahanian N; Link CJ
    J Immunother; 2008; 31(6):545-54. PubMed ID: 18528300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunological consequences of immunization with tumor lysate vaccine and propranolol as an adjuvant: A study on cytokine profiles in breast tumor microenvironment.
    Ashrafi S; Shapouri R; Mahdavi M
    Immunol Lett; 2017 Jan; 181():63-70. PubMed ID: 27899275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential administration of GM-CSF and IL-2 surface-modified MB49 cells vaccines against the metastatic bladder cancer.
    Shi X; Zhang X; Li J; Guo F; Hu Z; Jing Y; Bai L; Chen S; Wan P; Wang F; Gao J; Tan W
    Urol Oncol; 2013 Aug; 31(6):883-93. PubMed ID: 21924648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased immunogenicity of tumor-associated antigen, mucin 1, engineered to express alpha-gal epitopes: a novel approach to immunotherapy in pancreatic cancer.
    Deguchi T; Tanemura M; Miyoshi E; Nagano H; Machida T; Ohmura Y; Kobayashi S; Marubashi S; Eguchi H; Takeda Y; Ito T; Mori M; Doki Y; Sawa Y
    Cancer Res; 2010 Jul; 70(13):5259-69. PubMed ID: 20530670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Her-2 DNA versus cell vaccine: immunogenicity and anti-tumor activity.
    Whittington PJ; Radkevich-Brown O; Jacob JB; Jones RF; Weise AM; Wei WZ
    Cancer Immunol Immunother; 2009 May; 58(5):759-67. PubMed ID: 18836716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A New Humanized Mouse Model Mimics Humans in Lacking α-Gal Epitopes and Secreting Anti-Gal Antibodies.
    Saleh FM; Chandra PK; Lin D; Robinson JE; Izadpanah R; Mondal D; Bollensdorff C; Alt EU; Zhu Q; Marasco WA; Braun SE; Abdel-Motal UM
    J Immunol; 2020 Apr; 204(7):1998-2005. PubMed ID: 32144163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast cancer cells promote a notch-dependent mesenchymal phenotype in endothelial cells participating to a pro-tumoral niche.
    Ghiabi P; Jiang J; Pasquier J; Maleki M; Abu-Kaoud N; Halabi N; Guerrouahen BS; Rafii S; Rafii A
    J Transl Med; 2015 Jan; 13():27. PubMed ID: 25623554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and preclinical evaluation of a Bacillus Calmette-Guérin-MUC1-based novel breast cancer vaccine.
    Chung MA; Luo Y; O'Donnell M; Rodriguez C; Heber W; Sharma S; Chang HR
    Cancer Res; 2003 Mar; 63(6):1280-7. PubMed ID: 12649188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel HLA-A2-restricted CTL epitope of tumor-associated antigen L6 can inhibit tumor growth in vivo.
    Tu SH; Huang HI; Lin SI; Liu HY; Sher YP; Chiang SK; Chong P; Roffler S; Tseng GC; Chen HW; Liu SJ
    J Immunother; 2012 Apr; 35(3):235-44. PubMed ID: 22421941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo targeting of vaccinating tumor cells to antigen-presenting cells by a gene therapy method with adenovirus containing the alpha1,3galactosyltransferase gene.
    Deriy L; Ogawa H; Gao GP; Galili U
    Cancer Gene Ther; 2005 Jun; 12(6):528-39. PubMed ID: 15818383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.